Radiolabeled CCK/gastrin Peptides for Imaging and Therapy of CCK2 Receptor-expressing Tumors

Overview

Journal Amino Acids

Specialty Biochemistry

Date 2010 Mar 4

PMID 20198494

Citations 29

Authors

Susan Roosenburg

Peter Laverman

Floris L van Delft

Otto C Boerman

Affiliations

Soon will be listed here.

Abstract

Cholecystokinin (CCK) receptors are overexpressed in numerous human cancers, like medullary thyroid carcinomas, small cell lung cancers and stromal ovarian cancers. The specific receptor-binding property of the endogenous ligands for these receptors can be exploited by labeling peptides with a radionuclide and using these as carriers to guide the radioactivity to the tissues that express the receptors. In this way, tumors can be visualized using positron emission tomography and single photon emission computed tomography imaging. A variety of radiolabeled CCK/gastrin-related peptides has been synthesized and characterized for imaging. All peptides have the C-terminal CCK receptor-binding tetrapeptide sequence Trp-Met-Asp-Phe-NH(2) in common or derivatives thereof. This review focuses on the development and application of radiolabeled CCK/gastrin peptides for radionuclide imaging and radionuclide therapy of tumors expressing CCK receptors. We discuss both preclinical studies as well as clinical studies with CCK and gastrin peptides.

Citing Articles

Radiotheranostic landscape: A review of clinical and preclinical development.

Tran H, Yamaguchi A, Manning H Eur J Nucl Med Mol Imaging. 2025; .

PMID: 39891713 DOI: 10.1007/s00259-025-07103-7.

Personalised PET imaging in oncology: an umbrella review of meta-analyses to guide the appropriate radiopharmaceutical choice and indication.

Kirienko M, Gelardi F, Fiz F, Bauckneht M, Ninatti G, Pini C Eur J Nucl Med Mol Imaging. 2024; 52(1):208-224.

PMID: 39256216 PMC: 11599298. DOI: 10.1007/s00259-024-06882-9.

Effects of Side Chain and Peptide Bond Modifications on the Targeting Properties of Stabilized Minigastrin Analogs.

Zavvar T, Hormann A, Klingler M, Summer D, Rangger C, Desrues L Pharmaceuticals (Basel). 2023; 16(2).

PMID: 37052226 PMC: 9959130. DOI: 10.3390/ph16020278.

Effect of -Terminal Peptide Modifications on In Vitro and In Vivo Properties of Lu-Labeled Peptide Analogs Targeting CCK2R.

Hormann A, Klingler M, Rangger C, Mair C, Joosten L, Franssen G Pharmaceutics. 2023; 15(3).

PMID: 36986657 PMC: 10058949. DOI: 10.3390/pharmaceutics15030796.

Automated Synthesis of Ga-Labeled DOTA-MGS8 and Preclinical Characterization of Cholecystokinin-2 Receptor Targeting.

Hormann A, Plhak E, Klingler M, Rangger C, Pfister J, Schwach G Molecules. 2022; 27(6).

PMID: 35335396 PMC: 8949806. DOI: 10.3390/molecules27062034.

References

Froberg A, de Jong M, Nock B, Breeman W, Erion J, Maina T . Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2009; 36(8):1265-72. PMC: 2709231. DOI: 10.1007/s00259-009-1098-9. View

de Jong M, Bakker W, Bernard B, Valkema R, Kwekkeboom D, Reubi J . Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med. 2000; 40(12):2081-7. View

Behe M, Becker W, Gotthardt M, Angerstein C, Behr T . Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives. Eur J Nucl Med Mol Imaging. 2003; 30(8):1140-6. DOI: 10.1007/s00259-003-1178-1. View

Mather S, McKenzie A, Sosabowski J, Morris T, Ellison D, Watson S . Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy. J Nucl Med. 2007; 48(4):615-22. PMC: 2246928. DOI: 10.2967/jnumed.106.037085. View

Reubi J, Schaer J, Waser B . Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res. 1997; 57(7):1377-86. View

Breeman W, Froberg A, De Blois E, van Gameren A, Melis M, de Jong M . Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides. Nucl Med Biol. 2008; 35(8):839-49. DOI: 10.1016/j.nucmedbio.2008.09.006. View

Upp Jr J, Singh P, Townsend Jr C, Thompson J . Clinical significance of gastrin receptors in human colon cancers. Cancer Res. 1989; 49(2):488-92. View

Gotthardt M, Behe M, Beuter D, Battmann A, Bauhofer A, Schurrat T . Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2006; 33(11):1273-9. DOI: 10.1007/s00259-006-0157-8. View

Noble F, Wank S, Crawley J, Bradwejn J, Seroogy K, Hamon M . International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev. 1999; 51(4):745-81. View

10.

Innis R, Snyder S . Distinct cholecystokinin receptors in brain and pancreas. Proc Natl Acad Sci U S A. 1980; 77(11):6917-21. PMC: 350402. DOI: 10.1073/pnas.77.11.6917. View

11.

Imdahl A, Mantamadiotis T, Eggstein S, Farthmann E, Baldwin G . Expression of gastrin, gastrin/CCK-B and gastrin/CCK-C receptors in human colorectal carcinomas. J Cancer Res Clin Oncol. 1995; 121(11):661-6. DOI: 10.1007/BF01218524. View

12.

von Guggenberg E, Sallegger W, Helbok A, Ocak M, King R, Mather S . Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: preclinical evaluation. J Med Chem. 2009; 52(15):4786-93. DOI: 10.1021/jm900400w. View

13.

De Luca S, Saviano M, Moglie R, Digilio G, Bracco C, Aloj L . Conformationally constrained CCK8 analogues obtained from a rationally designed peptide library as ligands for cholecystokinin type B receptor. ChemMedChem. 2006; 1(9):997-1006. DOI: 10.1002/cmdc.200600054. View

14.

Roosenburg S, Laverman P, Joosten L, Eek A, Oyen W, de Jong M . Stabilized (111)in-labeled sCCK8 analogues for targeting CCK2-receptor positive tumors: synthesis and evaluation. Bioconjug Chem. 2010; 21(4):663-70. DOI: 10.1021/bc900465y. View

15.

Nock B, Maina T, Behe M, Nikolopoulou A, Gotthardt M, Schmitt J . CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs. J Nucl Med. 2005; 46(10):1727-36. View

16.

Smith J, Verderame M, McLaughlin P, Martenis M, Ballard E, Zagon I . Characterization of the CCK-C (cancer) receptor in human pancreatic cancer. Int J Mol Med. 2002; 10(6):689-94. View

17.

Kwekkeboom D, Bakker W, Kooij P, Erion J, Srinivasan A, de Jong M . Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med. 2000; 27(9):1312-7. DOI: 10.1007/s002590000296. View

18.

Behr T, Jenner N, Radetzky S, Behe M, Gratz S, Yucekent S . Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med. 1998; 25(4):424-30. DOI: 10.1007/s002590050241. View

19.

Noble F, Roques B . CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology. Prog Neurobiol. 1999; 58(4):349-79. DOI: 10.1016/s0301-0082(98)00090-2. View

20.

Laverman P, Behe M, Oyen W, Willems P, Corstens F, Behr T . Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors. Bioconjug Chem. 2004; 15(3):561-8. DOI: 10.1021/bc034208w. View